Ad scientiam's Newsletter is coming back !  
Get ready !

On rembobine

Green light in the United States for a genetic kit

Last 6 April, the American Agency for Drugs (FDA) authorized the commercialization of a genetic test directly accessible to patients on US soil. Launched by the company 23andMe, this test would determine our genetic predisposition to develop certain defined diseases. The principle is simple: patients must send a saliva sample to the company, DNA will be isolated and then tested to detect the presence or absence of certain variants defined as associated with an increased risk of developing a disease. It includes: Alzheimer's, Parkinson's disease, celiac disease, blood coagulation disorders, dystonia, hemochromatosis ...
Click here to learn more


"My Dose Coach": Sanofi stands out again in improving the management of diabetes.

Already well present on the diabetes market, Sanofi complete its diabetic accompaniment solutions with an application allowing them to calculate and monitor their insulin dose. Application, which was recently approved by the FDA. Although there are a number of applications available for insulin dose calculation, the majority have not received FDA approval, which allows Sanofi to stand out "My Dose Coach" from others Existing solutions in the management of diabetes.
Click here to learn more



FDA approval of the connected spirometer: GoSpiro®

This is a device developed by Monitored Therapeutics Inc. (MTI), similar to a conventional spirometer, but designed specifically for home use. GoSpiro has been validated clinically to measure several parameters of the quality of respiratory function at home with precision levels as robust as those present in hospital and laboratory structures. Then, the device transmits the data via Bluetooth to the patient's smartphone, tablet or computer while integrating the "GoHome MTI": a system in which patients and healthcare professionals can communicate via secure e-mail.
Click here to learn more

This application would increase drug adherence by 50% 

AiCure is developing a new method of approach to improve patients' adherence to their therapeutic treatment. Principle: the company uses a tablet or smartphone camera to film the patient taking his medication. An artificial intelligence system then analyzes the camera's data to ensure that the patient has taken the medication correctly and sends an alert if he forgets to do so. A 12-week study with 28 patients demonstrated that AiCure's artificial intelligence platform resulted in a 50% improvement in adherence to oral anticoagulants.

Click hère to learn more

A pocket nurse

The start-up Webbe launches an application to allow patients to be connected to an online nurse at any time. How does it work ? After sending the photographs of the wound, the user receives online advice from a nurse regarding the procedure to be followed to treat it, if necessary, the person is referred to the health network: pharmacy, medical office or hospital. This application, which can be reimbursed by its mutual, allows an initial diagnosis that will prevent patients from going unnecessarily to emergencies or to the doctor

Click hère to learn more

We liked this study
A recent study published in the Journal of Medical Internet Research including 1333 people has demonstrated the benefits of using mobile devices in the management of clinical trials Researchers at Peking University have developed a system for physicians to perform electronic data entry to facilitate the management of clinical trials. They found through the study of 1333 participants and 24 doctors that this system has a great potential to manage and coordinate clinical trials because of the ease of use for all those involved in a clinical trial. Real-time data capture and ease of use are beneficial to all those involved in the studies, including doctors with no experience in clinical trials. In addition, this data digitization provides a new approach to visualize clinical research data that was previously inaccessible.
Click here to access the full study
What's new for Adscientiam ?
Don't leave us without having read these (pithy) news of our precious Startup! We develop smartphone applications to support patients with chronic diseases. Our monitoring solutions empower patients and enrich the relationship between patient & physician. Icing on the cake, they are clinically validated ! Our asset? The ecosystem in which we operate. Located in the heart of the Pitié-Salpêtrière, incubated at the Institute of the Brain and the spinal cord (ICM), do not hesitate to come to meet us and to visit our Website!

These weeks, Ad Scientiam has been marked(???), among others, by the arrival of our beloved trainees, the return of our newsletter and the launch of a new study in atopic dermatitis ... to follow

A suggestion ? Write us at :-)

See you in 2 weeks! 

Hôpital de la Pitié-Salpêtrière
Institut du Cerveau et de la Moelle épinière (ICM)
47, Boulevard de l'Hôpital - Paris
E-mail : 
Téléphone : +33 (0)1 57 27 41 94
Copyright © 2017 Ad Scientiam, All rights reserved.